EX-10.18



 Exhibit 10.18 
 Prothena Biosciences Inc 
 REVISED –
December 21, 2012 
 Dear Gene: 
 Further to your Letter of Intent for Neotope Employment (dated September 26, 2012), I am pleased to confirm this offer to join Prothena Biosciences Inc1 (“Prothena” or the “Company”), commencing on the
day following the closing date of the demerger (the “Transaction”) of the Company (and its affiliates) from Elan Corporation, plc – which occurred on December 20, 2012. 
 We are confident in your knowledge, expertise and judgment, and believe your performance will meet the high-quality objectives and standards set by Prothena leadership and management. You will be employed
as Chief Scientific Officer and Head of Research & Development, reporting to me, although your duties and title may change, based on the Company’s needs and priorities. This is a full-time, exempt position. 

Your original date of hire with Elan and its subsidiaries will remain as your original date of hire within Prothena’s programs relating to
employment, compensation and employee benefit plans. 
 Your starting salary will be $340,000.00 annually, paid twice per month. Your pay
is subject to applicable taxes and withholdings. 
 Prothena embraces a pay-for-performance philosophy. All employees are currently eligible for
an annual cash bonus under the terms of the Company’s cash incentive plan (Prothena Biosciences Inc Incentive Compensation Plan). Cash incentive awards are determined by a number of factors, including industry competitiveness, Prothena’s
business strategy, and the degree to which Company, function and/or individual goals are met. The target bonus opportunity for your position is currently 40% of plan year salaried-earnings. A condition to earning a cash incentive award is
that an employee remains employed through the pay date of the award, which will be not later than March 15 in the year following the conclusion of the plan year. The cash bonus plan is operated at the sole discretion of Prothena, is subject to
review on a regular basis and may change from time to time. 
 You will be eligible to receive an equity award of
200,0002 stock options in connection with your
commencement of employment following the Transaction. This award is at the discretion of the Prothena Board of Directors and is subject to its approval, the terms of the Company’s equity incentive plan (Prothena Corporation plc 2012 Long
Term Incentive Plan), and the Company’s standard equity award agreement. The Exercise Price will be set as the average of the closing price of Prothena’s ordinary shares for the first 25 trading days commencing on the first day of trading
on the NASDAQ Global Market listing. The Grant Date will be the 25th trading
day.3 The award will vest 25% after the first year of
active service from the Grant Date, and monthly at a rate of 1/48th of the award thereafter, such that the award will fully vest after a four-year period of continuous employment. 
 On the first day of the month following your Start Date of employment, you will be eligible to participate in Prothena’s comprehensive benefits program, including the company’s health and
welfare and retirement benefit plans. Details about these and other applicable plans will be provided separately, as will further information regarding certain onboarding items and other documents needed before your Start Date (e.g., direct deposit
election, W-4 allowances, Employee Proprietary Information and Invention Assignment Agreement). 
  

	1 	The legal entity Neotope Biosciences, Inc. was renamed Prothena Biosciences Inc on November 1, 2012 


	2 	This represents slightly more than 1.10% of Prothena’s expected common shares outstanding post Transaction. 


	3 	Assumes approval on Start Date by Prothena’s Board of Directors; should approval occur at a later date, the 25-day period would start on the date of approval.









 Prothena Biosciences Inc 
 Your employment is “at will.” This means that you or Prothena each has the right to terminate the employment relationship at any time, with or without cause. Nothing in this letter should be
taken as a guarantee of continued employment or a specific term of employment. Further, all benefits and compensation provided by the Company are contingent upon your continued employment. 
 To accept our offer, please sign this letter and return to Kevin Hickey. By signing this letter, you acknowledge that it sets out our entire agreement between the parties and supersedes all prior oral and
written agreements, understandings, commitments and practices between the parties, including the Letter of Intent for Neotope Employment dated September 26, 2012. No amendments to this agreement may be made except in writing signed by a
duly authorized representative of Prothena. 
 We look forward to having you join Prothena. If you have any questions, or would like additional
information to help you reach a decision, please feel free to contact Kevin at (650) 278-1762. 
 Sincerely, 

/s/ Dale Schenk 
 Dale Schenk 

President and CEO 
 Prothena Biosciences Inc

 ACCEPTANCE: 
  

					
			
	/s/ Gene Kinney	 		 	12/22/2012
	Gene Kinney	 		 	Date